Program
niraparib
Also written as “Niraparib”, “MK-4827” and “ZL-2306(nirapairb)”.
Its studies are mostly in Ovarian Neoplasms · Neoplasms · Prostatic Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by 6 companies.
Drug pageNiraparib: every studyMany companies study it; this page follows only the 39 they lead. All 151 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 236 open or running | phase 4since Mar 19, 2025 | Sep 5, 2008 | Nov 26, 2026phase 3 · NCT03981796 |
| Johnson & Johnson | 53 open or running | phase 3since Nov 19, 2018 | Aug 1, 2016 | none ahead |
| Zai Lab | 50 open or running | phase 3since Apr 23, 2018 | Apr 20, 2018 | none ahead |
| Takeda | 30 open or running | phase 2since Nov 29, 2018 | Apr 5, 2018 | none ahead |
| Merck | 20 open or running | phase 1since Oct 21, 2010 | Oct 21, 2010 | none ahead |
| Tempus AI | 10 open or running | phase 2since Dec 13, 2021 | Dec 13, 2021 | none ahead |
Also a collaborator on its studies: Myriad Genetics, Sarah Cannon Research Institute, Sarah Cannon and Myriad Genetic Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 23 studies since Sep 5, 2008.
- Sep 19, 20182 phase 3 studiesZai Lab · NCT03709316, NCT03705156
- Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT03748641 · 765 enrolled · United States, Argentina, Australia and more
- Nov 29, 20182 phase 2 studies in Ovarian NeoplasmsTakeda · NCT03759600, NCT03759587
- May 31, 2019Phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796 · 785 enrolled · United States, Belarus, Belgium and more
- May 13, 2020Phase 2 study in Ovarian NeoplasmsZai Lab · NCT04392102 · 15 enrolled · China
- Jul 14, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungGlaxoSmithKline · NCT04475939 · 666 enrolled · United States, Argentina, Australia and more
- Jul 31, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04497844 · 696 enrolled · United States, Argentina, Australia and more
- Sep 4, 2020Phase 1 study in NeoplasmsGlaxoSmithKline · NCT04544995 · 47 enrolled · United Kingdom
- Oct 5, 2020Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT04577833 · 136 enrolled · United States, Belgium, France and more
- Nov 20, 2020Phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT04641247 · 37 planned · United States, Austria, Canada and more
- Jun 1, 2021Phase 3 study in Breast NeoplasmsGlaxoSmithKline · NCT04915755 · 40 enrolled · United States, Argentina, Australia and more
- Dec 13, 2021Tempus AI’s first study: phase 2 study in Breast NeoplasmsNew to Tempus AITempus AI · NCT05169437 · 22 enrolled · United States
- Mar 19, 2025Phase 4 study in Ovarian NeoplasmsGlaxoSmithKline · NCT06887933 · 67 planned
- Apr 30, 2025Phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT06964165 · 36 enrolled · United States, Canada, Spain
Ahead
- Nov 26, 2026Primary completion: phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796
- Dec 28, 2026Primary completion: phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT04641247
TargetBeta
“Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06964165Ovarian Neoplasms · United States, Canada, Spain | 2 | Terminated | GlaxoSmithKline | Jun 28, 2024 | 36 |
| NCT06887933Ovarian Neoplasms | 4 | Not yet recruiting | GlaxoSmithKline | Mar 20, 2026 | 67 |
| NCT05169437Breast Neoplasms · United States | 2 | Terminated | Tempus AI | Aug 6, 2024 | 22 |
| NCT04915755Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 28, 2024 | 40 |
| NCT04641247Ovarian Neoplasms · United States, Austria, Canada and more | 2 | Recruiting | GlaxoSmithKline | Dec 28, 2026 | 37 |
| NCT04577833Prostatic Neoplasms · United States, Belgium, France and more | 1 | Active, not recruiting | Johnson & Johnson | Oct 15, 2021 | 136 |
| NCT04544995Neoplasms · United Kingdom | 1 | Terminated | GlaxoSmithKline | Apr 23, 2025 | 47 |
| NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 7, 2025 | 696 |
| NCT04475939Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Feb 26, 2025 | 666 |
| NCT04392102Ovarian Neoplasms · China | 2 | Completed | Zai Lab | Apr 8, 2021 | 15 |
| NCT03981796Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Nov 26, 2026 | 785 |
| NCT03759600Ovarian Neoplasms · Japan | 2 | Completed | Takeda | Dec 28, 2022 | 20 |
| NCT03759587Ovarian Neoplasms · Japan | 2 | Completed | Takeda | Mar 17, 2019 | 19 |
| NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 8, 2021 | 765 |
| NCT03709316Ovarian Neoplasms · China | 3 | UNKNOWN | Zai Lab | Jan 29, 2022 | 384 |
| NCT03705156Platinum-sensitive Relapsed Ovarian Cancer · China | 3 | UNKNOWN | Zai Lab | Feb 1, 2020 | 265 |
| NCT03602859Ovarian Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Oct 31, 2024 | 1,400 |
| NCT03516084Small Cell Lung Carcinoma · China | 3 | Terminated | Zai Lab | Feb 21, 2020 | 185 |
| NCT03551171Ovarian Neoplasms · China | 1 | Completed | Zai Lab | May 3, 2018 | 42 |
| NCT03497429Advanced Solid Tumors · Japan | 1 | Completed | Takeda | Feb 10, 2020 | 9 |
| NCT03329001Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Dec 30, 2021 | 236 |
| NCT03329937Breast Neoplasms | 1 | Completed | GlaxoSmithKline | Jan 2, 2020 | 21 |
| NCT03326193Ovarian Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Dec 24, 2020 | 105 |
| NCT03359850Ovarian Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Sep 16, 2019 | 17 |
| NCT03308942Neoplasms · United States | 2 | Completed | GlaxoSmithKline | May 4, 2020 | 53 |
| NCT02924766Prostatic Neoplasms · United States, Canada | 1 | Completed | Johnson & Johnson | Jul 18, 2019 | 34 |
| NCT02854436Prostatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Johnson & Johnson | Jan 26, 2021 | 289 |
| NCT02657889Neoplasms · United States | 2 | Completed | GlaxoSmithKline | May 14, 2018 | 122 |
| NCT02655016Ovarian Neoplasms · United States, Belgium, Denmark and more | 3 | Active, not recruiting | GlaxoSmithKline | May 17, 2019 | 733 |
| NCT02476552Neoplasms · Netherlands | 1 | Completed | GlaxoSmithKline | Dec 2015 | 12 |
| NCT02354586Ovarian Neoplasms · United States, Canada | 2 | Completed | GlaxoSmithKline | Feb 28, 2018 | 463 |
| NCT01905592Breast Neoplasms · United States, Belgium, Canada and more | 3 | Terminated | GlaxoSmithKline | May 23, 2018 | 216 |
| NCT01847274Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 22, 2016 | 596 |
| NCT01294735Glioblastoma | 1 | Completed | Merck | Apr 2012 | 19 |
| NCT01244009Lymphoma | 2 | Withdrawn | GlaxoSmithKline | Aug 2013 | 0 |
| NCT01227941Ovarian Neoplasms | 1 | Terminated | GlaxoSmithKline | Sep 2011 | 6 |
| NCT01226901Neoplasms | 1 | Terminated | Merck | Feb 2011 | 3 |
| NCT01110603Neoplasms | 1 | Terminated | GlaxoSmithKline | Jul 2011 | 12 |
| NCT00749502Leukemia, Lymphocytic, Chronic, B-Cell | 1 | Completed | GlaxoSmithKline | Sep 2011 | 113 |
How it is read
Names in the registry
- “Niraparib”, 25 entries
- “MK-4827”, 5 entries
- “ZL-2306(nirapairb)”, 2 entries
- “niraparib”, 2 entries
- “MK-4827 + pegylated liposomal doxorubicin”, 2 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 18 studies
- Neoplasms, 9 studies
- Prostatic Neoplasms, 4 studies
- Breast Neoplasms, 3 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.